1) MLT001 Petronek et al. (2021) Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy. Redox Biology 42:101864. (link)
2) MLT002 Di Bella et al. (2013) Melatonin Anticancer Effects: Review. International Journal of Molecular Science 14, 2410-2430. (link)
3) MLT003 Kvietkauskas et al. (2020) The role of melatonin in colorectal cancer treatment: a comprehensive review. Therapeutic Advances in Medical Oncology 12: 1 –14. (link)
4) MLT004 Wang et al. (2019) Melatonin inhibits lung metastasis of gastric cancer in vivo. Biomedicine & Pharmacotherapy 117, 109018. (link)
5) MLT005 Chen et al. (2020) Melatonin suppresses epithelial to mesenchymal transition in the MG-63 cell line. Molecular Medicine Reports 21: 1356-1364. (link)
6) MLT006 Cheng et al. (2019) Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1α/ROS/VEGF. International Journal of Molecular Medicine 43: 945-955. (link)
7) MLT007 Zharinov et al. (2020) Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. Oncotarget, 11( 41): 3723-3729. (link)
8) MLT008 Maroufi et al. (2020) The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. Pathology – Research and Practice 216 (2020) 153226. (link)
9) MLT009 Liu et al. (2018) “Melatonin Inhibits Reactive Oxygen Species-Driven Proliferation, Epithelial-Mesenchymal Transition, and Vasculogenic mimicry in Oral Cancer”. Oxidative Medicine and Cellular Longevity, 3510970. (link)
10) MLT010 Fathizadeh et al. (2019) “Melatonin: an anti-tumor agent for osteosarcoma”. Cancer Cell International 19, 319 (link)
11) MLT011 de Godoy et al. (2023) “Azioni sinergiche di Alpelisib e Melatonina nelle linee cellulari di carcinoma mammario con mutazione del gene PIK3CA – Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation”. Life Science 324, 121708. (link)
12) MLT012 Megerian et al. (2023) “Melatonina e cancro alla prostata: ruoli antitumorali e applicazione terapeutica – Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application” Aging and Disease 14(3): 840-857 (link)
13) MLT013 Wang et al. (2022) “Uso della melatonina nei trattamenti antitumorali: a che punto siamo? – Use of Melatonin in Cancer Treatment: Where Are We?” International Journal of Molecular Science 23, 3779. (link)
14) MLT014 Fernández-Palanca et al. (2022) “Melatonina come agente antitumorale contro il cancro al fegato: una revisione aggiornata – Melatonin as an Antitumor Agent against Liver Cancer: An Updated Systematic Review.” Antioxidants 10(1), 103 (link)
15) MLT015 Di Bella et al. (1997) ““Melatonina con adenosina solubilizzata in acqua e stabilizzata con glicina per il trattamento oncologico: preparazione tecnica, efficacia e risultati clinici”. Neuroendocrinology Letters 2017; 38(7):465–474. (link)
16) MLT016 Kvetnoy et al. (1997) “Commentario: Il sistema neuroendocrino diffuso e la melatonina extrapineale – Commentary: The diffuse neuroendocrine system and extrapineal melatonin” Journal of Molecular Endocrinology 18, 1–3. (link)
17) MLT017 Kvetnoy (2002) “Melatonina extrapineale in patologia: nuove prospettive per la diagnosi, la prognosi e il trattamento della malattia – Extrapineal melatonin in pathology: New perspectives for diagnosis, prognosis and treatment of illness”. Neuroendocrinology Letters 23(Suppl 1): 92-96. (link)
18) MLT018 Kvetnoy et al. (2002) “La melatonina come pietra angolare della Neuroimmunoendocrinologia – Melatonin as the Cornerstone of Neuroimmunoendocrinology”. International Journal of Molecular Sciences 23(3), 1835. (link)
19) MLT019 Qadir et al. (2024) “Valutazione dei livelli di melatonina e antiossidanti nel siero di pazienti con cancro al seno – Evaluation of Melatonin and Antioxidant Levels in the Serum of Breast Cancer Patient”. BioMed Target Journal 2(1): 35-42. (link)
20) MLT020 de Marais et al. (2024) “Svelare l’impatto del trattamento con melatonina: stress ossidativo, risposte metaboliche e cambiamenti morfologici nelle cellule del carcinoma epatocellulare HuH7.5 – Unraveling the impact of melatonin treatment: Oxidative stress, metabolic responses, and morphological changes in HuH7.5 hepatocellular carcinoma cells”, pubblicato su Pathology – Research and Practice a Gennaio 2024, 253: 155056. (link)
Articoli del blog in “Melatonina
